{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:06:02Z","timestamp":1788959162066,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Vonoprazan-amoxicillin (VA) dual therapy has recently been proposed to eradicate\n                      <jats:italic toggle=\"yes\">Helicobacter pylori (H. pylori)<\/jats:italic>\n                      with controversial results. We, therefore, conducted a meta-analysis to assess the effect of this therapy for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We searched PubMed, Embase, Cochrane Library, and Web of Science database from inception until November 2022, collecting randomized controlled trials (RCTs) comparing VA dual therapy with other regimens for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication. Pooled relative risks (RRs) were calculated using random effects model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five RCTs were ultimately included. Compared with the vonoprazan-amoxicillin-clarithromycin (VAC) triple therapy, the eradication rate of VA dual therapy was lower in intention-to-treat (ITT) analysis (n = 3 RCTs, RR = 0.94, 95% CI: 0.88\u20130.99,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), but there was no significant difference between them in the per-protocol (PP) analysis (RR = 0.96, 95% CI: 0.91\u20131.01,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.11). For clarithromycin-resistant\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      strains, the eradication rate of VA dual therapy was significantly higher than that of the VAC triple therapy (n = 2 RCTs, RR = 1.20, 95% CI: 1.03\u20131.39,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). Compared with the PPI-based triple therapy (PAC), VA dual therapy had a superior eradication rate (n = 2 RCTs, ITT analysis RR = 1.13, 95% CI: 1.04\u20131.23,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003; PP analysis pooled RR = 1.14, 95% CI: 1.06\u20131.22,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0004). Compared with VAC or PAC triple therapy, VA dual therapy has a similar incidence of total adverse events and compliance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>VA dual therapy had a similar effect compared to VAC triple therapy and was superior to PAC triple therapy. Future RCTs are needed to ascertain the optimal dosage and duration of vonoprazan and amoxicillin, and the effect of VA dual therapy compared with the mainstream regimens recommended by current guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_153_23","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T06:07:46Z","timestamp":1691647666000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.4103","volume":"29","author":[{"given":"Ben-Gang","family":"Zhou","sequence":"first","affiliation":[{"name":"Dalian Medical University, Dalian, Liaoning Province, China"},{"name":"Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Zhou","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The People\u2019s Hospital of China Three Gorges University, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Jing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The People\u2019s Hospital of China Three Gorges University, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-3034","authenticated-orcid":false,"given":"Yan-Bing","family":"Ding","sequence":"additional","affiliation":[{"name":"Dalian Medical University, Dalian, Liaoning Province, China"},{"name":"Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of helicobacter pylori infection:Systematic review and meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMcp1710945","article-title":"Helicobacter pylori infection","volume":"380","author":"Crowe","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20240829","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection:The Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection:The Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA clinical practice update on the management of refractory helicobacter pylori infection:Expert review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in helicobacter pylori:A systematic review and meta-analysis in World Health Organization Regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline:Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/sjg.SJG_292_17","article-title":"Failure of optimized dual proton pump inhibitor amoxicillin therapy:What now","volume":"23","author":"Graham","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"17562848221147756","DOI":"10.1177\/17562848221147756","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication:A systematic review and meta-analysis with trial sequential analysis","volume":"16","author":"Zhou","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article:Potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"799","DOI":"10.5009\/gnl20242","article-title":"Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of helicobacter pylori eradication?","volume":"15","author":"Sue","year":"2021","journal-title":"Gut Liver"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/jgh.15252","article-title":"Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance","volume":"36","author":"Graham","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jgh.15917","article-title":"Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication:A systematic review and meta-analysis","volume":"37","author":"Ouyang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"17562848221125308","DOI":"10.1177\/17562848221125308","article-title":"Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy:A systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement:An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE:An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R23-20240829","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment:A multicentre randomised trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe:Randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"e12896","DOI":"10.1111\/hel.12896","article-title":"Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pylori infection in China:A prospective, randomized clinical pilot study","volume":"27","author":"Hu","year":"2022","journal-title":"Helicobacter"},{"key":"R27-20240829","doi-asserted-by":"crossref","first-page":"987","DOI":"10.21037\/atm-22-4133","article-title":"The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori:An open, multicenter, randomized clinical study","volume":"10","author":"Lin","year":"2022","journal-title":"Ann Transl Med"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","article-title":"Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for helicobacter pylori eradication:A randomized control trial","volume":"38","author":"Zuberi","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication:A phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial:Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TaK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R31-20240829","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00228-022-03430-y","article-title":"Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori:A meta-analysis of randomized clinical trials","volume":"79","author":"Sun","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1159\/000502287","article-title":"Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori","volume":"101","author":"Furuta","year":"2020","journal-title":"Digestion"},{"key":"R35-20240829","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","article-title":"Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naive cohort of junior high school students in Japan","volume":"55","author":"Gotoda","year":"2020","journal-title":"J. Gastroenterol"},{"key":"R36-20240829","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.14309\/00000434-201710001-01232","article-title":"Vonoprazan-based dual therapy with amoxicillin is as effective as the triple therapy for eradication of H pylori","volume":"112","author":"Furuta","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R37-20240829","first-page":"S29","article-title":"Vonoprazan-based dual therapy with amoxicillin is as effective as the triple therapy for eradication of H pylori","volume":"101","author":"Furuta","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R38-20240829","first-page":"S-927","article-title":"Vonoprazan-based dual therapy with amoxicillin is as effective as the triple therapy for the eradication of H pylori","volume":"154","author":"Furuta","year":"2018","journal-title":"Gastroenterology"},{"key":"R39-20240829","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021:A systematic review and meta-analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R40-20240829","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/pathogens11070786","article-title":"Primary antibiotic resistance of helicobacter pylori in different regions of China:A systematic review and meta-analysis","volume":"11","author":"Chen","year":"2022","journal-title":"Pathogens"},{"key":"R41-20240829","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/PMC.S14459","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect Medicin Chem"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_153_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:10:23Z","timestamp":1787757023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_153_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_153_23","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"2023-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}